Home › Funds › SEIZERT CAPITAL PARTNERS, LLC › NBIX

SEIZERT CAPITAL PARTNERS, LLC position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

SEIZERT CAPITAL PARTNERS, LLC reported holding 358,817 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$50.9M, representing 2.21% of its reported portfolio and ranking #16 among its reported holdings. SEIZERT CAPITAL PARTNERS, LLC has disclosed NBIX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)358.82K sh
Reported value held$50.89M
Portfolio Weight2.21%
First reportedQ3 2025
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SEIZERT CAPITAL PARTNERS, LLC's NBIX position evolved

SEIZERT CAPITAL PARTNERS, LLC first disclosed a stake in NBIX in Q3 2025 at 70,035 shares (US$9.8M). The position peaked in Q3 2026 at 358,817 shares, worth US$50.9M. Across 5 filings, SEIZERT CAPITAL PARTNERS, LLC increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 358,817 shares valued at US$50.9M — an increase of 81,480 shares quarter over quarter.. Notable position changes include a 216% increase in Q2 2026 (shares fell 16% over the following quarter), a 29% increase in Q3 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 70.03K $9.83M New
Q4 2025 70.67K $10.02M Add
Q1 2026 87.66K $11.55M Add
Q2 2026 277.34K $46.74M Add
Q3 2026 358.82K $50.89M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 30 other funds we track also report a position in NBIX — the largest reported positions include Two Sigma Investments (US$349.9M), Renaissance Technologies (US$326.3M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has SEIZERT CAPITAL PARTNERS, LLC held NBIX?

SEIZERT CAPITAL PARTNERS, LLC has disclosed NBIX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is SEIZERT CAPITAL PARTNERS, LLC's current position in NBIX?

As of Q3 2026, SEIZERT CAPITAL PARTNERS, LLC holds 358.82K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $50.89M, representing 2.21% of its reported portfolio and ranking #16.

Has SEIZERT CAPITAL PARTNERS, LLC been buying or selling NBIX?

In the latest 13F filing (Q3 2026), SEIZERT CAPITAL PARTNERS, LLC increased its position in NBIX. The position peaked in Q3 2026 at 358.82K shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Two Sigma Investments, Renaissance Technologies, Vestal Point Capital, LP, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.